Accordingly, there is evidence that SMN function is regulated both in vivo and in vitro[45], [46] and that targeting downstream defects induced by SMN deficiency without increasing SMN levels can be beneficial in animal models of SMA [10], [11], [47]–[50]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.